MSH|^~\&#|LOI_NG_PRU_PROFILE^2.16.840.1.113883.9.87^ISO|LOI_NG_PRU_PROFILE^2.16.840.1.113883.9.87^ISO|LOI_NG_PRU_PROFILE^2.16.840.1.113883.9.87^ISO|LOI_NG_PRU_PROFILE^2.16.840.1.113883.9.87^ISO|20170927174746.1984+0530||ORU^R01^ORU_R01|MessageID123|P|2.5.1|||AL|AL|||||PHLabReport-Ack^LOI_NG_PRU_PROFILE^2.16.840.1.113883.9.11^ISO|SFT|HC|HC|HC|HC|||PID|1||1^2^ISO^LOI_NG_PRU_PROFILE&2.16.840.1.113883.9.87&ISO^ANC||Singh^Asish^k||20170101000000+0530|ORC|RE|ORD170^NDA^2.16.840.1.113883.9.87^ISO|257^8^2.16.840.1.113883.9.87^ISO|||F||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^|||||||||HC|HC|^BPN^BP^BP^^^|OBR|1|ORD170^NDA^2.16.840.1.113883.9.87^ISO|257^8^2.16.840.1.113883.9.87^ISO|31019-3^Test0001^LN|||20170820000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170827000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|2|ORD170^NDA^2.16.840.1.113883.9.87^ISO|259^8^2.16.840.1.113883.9.87^ISO|31019-3^Test 22^LN|||20170819000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170826000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|3|ORD170^NDA^2.16.840.1.113883.9.87^ISO|260^8^2.16.840.1.113883.9.87^ISO|31019-3^Test 2^LN|||20170823000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170830000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|4|ORD170^NDA^2.16.840.1.113883.9.87^ISO|261^8^2.16.840.1.113883.9.87^ISO|31019-3^Test 2^LN|||20170824133000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170831133000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|5|ORD170^NDA^2.16.840.1.113883.9.87^ISO|262^8^2.16.840.1.113883.9.87^ISO|31019-3^Test 3^LN|||20170127123000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170203123000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|6|ORD170^NDA^2.16.840.1.113883.9.87^ISO|263^8^2.16.840.1.113883.9.87^ISO|31019-3^Test 4^LN|||20170816133000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170823133000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|7|ORD170^NDA^2.16.840.1.113883.9.87^ISO|264^8^2.16.840.1.113883.9.87^ISO|31019-3^Test 4^LN|||20170823133000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170830133000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|8|ORD170^NDA^2.16.840.1.113883.9.87^ISO|265^8^2.16.840.1.113883.9.87^ISO|31019-3^Test 3^LN|||20170823133000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170830133000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|9|ORD170^NDA^2.16.840.1.113883.9.87^ISO|266^8^2.16.840.1.113883.9.87^ISO|31019-3^sdf^LN|||20170731133000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170807133000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|10|ORD170^NDA^2.16.840.1.113883.9.87^ISO|267^8^2.16.840.1.113883.9.87^ISO|31019-3^Test del^LN|||20170823133000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170830133000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|11|ORD170^NDA^2.16.840.1.113883.9.87^ISO|268^8^2.16.840.1.113883.9.87^ISO|31019-3^Test 6^LN|||20170826133000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170902133000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|12|ORD170^NDA^2.16.840.1.113883.9.87^ISO|269^8^2.16.840.1.113883.9.87^ISO|31019-3^Test 7^LN|||20170826000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170902000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|13|ORD170^NDA^2.16.840.1.113883.9.87^ISO|270^8^2.16.840.1.113883.9.87^ISO|31019-3^Test 1^LN|||20170815000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170822000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|14|ORD170^NDA^2.16.840.1.113883.9.87^ISO|271^8^2.16.840.1.113883.9.87^ISO|31019-3^Test 88^LN|||20170831000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170907000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|15|ORD170^NDA^2.16.840.1.113883.9.87^ISO|272^8^2.16.840.1.113883.9.87^ISO|31019-3^Test 9^LN|||20170817000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170824000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|16|ORD170^NDA^2.16.840.1.113883.9.87^ISO|273^8^2.16.840.1.113883.9.87^ISO|31019-3^Test Name^LN|||20170906000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170913000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|17|ORD170^NDA^2.16.840.1.113883.9.87^ISO|274^8^2.16.840.1.113883.9.87^ISO|31019-3^Test name^LN|||20170907000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170914000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|18|ORD170^NDA^2.16.840.1.113883.9.87^ISO|275^8^2.16.840.1.113883.9.87^ISO|31019-3^Test 11^LN|||20170902000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170909000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|19|ORD170^NDA^2.16.840.1.113883.9.87^ISO|276^8^2.16.840.1.113883.9.87^ISO|31019-3^Name^LN|||20170905000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170912000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|20|ORD170^NDA^2.16.840.1.113883.9.87^ISO|277^8^2.16.840.1.113883.9.87^ISO|31019-3^Test 2^LN|||20170905000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170912000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|21|ORD170^NDA^2.16.840.1.113883.9.87^ISO|278^8^2.16.840.1.113883.9.87^ISO|31019-3^Test 10^LN|||20170906000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170913000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|22|ORD170^NDA^2.16.840.1.113883.9.87^ISO|279^8^2.16.840.1.113883.9.87^ISO|31019-3^sugar test^LN|||20170920000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170927000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|23|ORD170^NDA^2.16.840.1.113883.9.87^ISO|280^8^2.16.840.1.113883.9.87^ISO|31019-3^sugar test^LN|||20170913000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170920000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|24|ORD170^NDA^2.16.840.1.113883.9.87^ISO|281^8^2.16.840.1.113883.9.87^ISO|31019-3^sugar test^LN|||20170913000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170920000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|25|ORD170^NDA^2.16.840.1.113883.9.87^ISO|282^8^2.16.840.1.113883.9.87^ISO|31019-3^sugar test^LN|||20170913000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170920000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|26|ORD170^NDA^2.16.840.1.113883.9.87^ISO|283^8^2.16.840.1.113883.9.87^ISO|31019-3^sugar test^LN|||20170913000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170920000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|27|ORD170^NDA^2.16.840.1.113883.9.87^ISO|284^8^2.16.840.1.113883.9.87^ISO|31019-3^sugar test^LN|||20170913000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170920000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|28|ORD170^NDA^2.16.840.1.113883.9.87^ISO|285^8^2.16.840.1.113883.9.87^ISO|31019-3^sugar test^LN|||20170202000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170209000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|29|ORD170^NDA^2.16.840.1.113883.9.87^ISO|286^8^2.16.840.1.113883.9.87^ISO|31019-3^sugar test^LN|||20170202000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170209000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|30|ORD170^NDA^2.16.840.1.113883.9.87^ISO|287^8^2.16.840.1.113883.9.87^ISO|31019-3^sugar test^LN|||20170202000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170209000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|31|ORD170^NDA^2.16.840.1.113883.9.87^ISO|288^8^2.16.840.1.113883.9.87^ISO|31019-3^sugar test^LN|||20170202000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170209000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|32|ORD170^NDA^2.16.840.1.113883.9.87^ISO|289^8^2.16.840.1.113883.9.87^ISO|31019-3^sugar test^LN|||20170202000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170209000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|33|ORD170^NDA^2.16.840.1.113883.9.87^ISO|290^8^2.16.840.1.113883.9.87^ISO|31019-3^sugar test^LN|||20170202000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170209000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|34|ORD170^NDA^2.16.840.1.113883.9.87^ISO|291^8^2.16.840.1.113883.9.87^ISO|31019-3^10-Hydroxycarbazepine [Mass/?volume] in Serum or Plasma^LN|||20170202000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170209000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|35|ORD170^NDA^2.16.840.1.113883.9.87^ISO|292^8^2.16.840.1.113883.9.87^ISO|31019-3^10-Hydroxycarbazepine [Mass/?volume] in Serum or Plasma^LN|||20170101000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170108000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|36|ORD170^NDA^2.16.840.1.113883.9.87^ISO|293^8^2.16.840.1.113883.9.87^ISO|31019-3^10-Hydroxycarbazepine [Mass/?volume] in Serum or Plasma^LN|||20170101000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170108000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|37|ORD170^NDA^2.16.840.1.113883.9.87^ISO|294^8^2.16.840.1.113883.9.87^ISO|31019-3^10-Hydroxycarbazepine [Mass/?volume] in Serum or Plasma^LN|||20170101000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170108000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|38|ORD170^NDA^2.16.840.1.113883.9.87^ISO|295^8^2.16.840.1.113883.9.87^ISO|31019-3^10-Hydroxycarbazepine [Mass/?volume] in Serum or Plasma^LN|||20170101000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170108000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|39|ORD170^NDA^2.16.840.1.113883.9.87^ISO|296^8^2.16.840.1.113883.9.87^ISO|31019-3^10-Hydroxycarbazepine [Mass/?volume] in Serum or Plasma^LN|||20170101000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170108000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|40|ORD170^NDA^2.16.840.1.113883.9.87^ISO|297^8^2.16.840.1.113883.9.87^ISO|31019-3^10-Hydroxycarbazepine [Mass/?volume] in Serum or Plasma^LN|||20170101000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170108000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|41|ORD170^NDA^2.16.840.1.113883.9.87^ISO|298^8^2.16.840.1.113883.9.87^ISO|31019-3^10-Hydroxycarbazepine [Mass/?volume] in Serum or Plasma^LN|||20170202000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170209000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|42|ORD170^NDA^2.16.840.1.113883.9.87^ISO|299^8^2.16.840.1.113883.9.87^ISO|31019-3^10-Hydroxycarbazepine [Mass/?volume] in Serum or Plasma^LN|||20170101000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170108000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|43|ORD170^NDA^2.16.840.1.113883.9.87^ISO|300^8^2.16.840.1.113883.9.87^ISO|31019-3^10-Hydroxycarbazepine [Mass/?volume] in Serum or Plasma^LN|||20170101000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170108000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|OBR|44|ORD170^NDA^2.16.840.1.113883.9.87^ISO|301^8^2.16.840.1.113883.9.87^ISO|31019-3^10-Hydroxycarbazepine [Mass/?volume] in Serum or Plasma^LN|||20170101000000+0530|||||||||2^Jakson^Micheal^Z^^DR^MD^sourcetable^NIST-AA-1&2.16.840.1.113883.9.87&ISO^A^57422^^MD^NIST-AA-1&2.16.840.1.113883.9.87&ISO^||||||20170108000000+0530|||A|OBX|1|ST|59784-9^Vaccine funding program eligibility category^LN|HC|5.5||2.5-5.3|S^Susceptible^HL70078|||C|||20170101000000+0530|LP^Lab Partners^ICD10CA^AnyTown^CA^ICD10CA^MedicalDirector^(555)555-1212||||||||HC|HC|HC|SPM|1|HC^HC&HC&2.16.840.1.113883.9.87&ISO||UR^Urine^HL70487|||||||||||||20170101000000+0530|20170302000000+0530|